Clinical Trial Update: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating selinexor with alternating bortezomib or lenalidomide plus dexamethasone in newly diagnosed multiple myeloma; currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Selinexor (selinexor)

Snippet

Sponsor: Ida Bruun Kristensen | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING